- HPV in the oral cavity is common among sexually active female adolescents, but declines with age, time since first sexual activity.
Why this matters
- Consider postdiagnosis HPV testing in the oral cavity.
- Continue to encourage HPV vaccine uptake in eligible adolescent, young adult patients.
- 1259 participants, 50.7% (638), 45.2% (569), 3.4% (43), respectively, of African-American, Hispanic, unspecified race/identify.
- Median age 18 years (range 13-21).
- >50% reported first sexual experience at median 14.8 years.
- 6.2% (78; 95% CI, 4.9%-7.7%) had oral HPV; greatest prevalence detected at age 16 for all types (10.5%, 16/153), oncogenic types (3.9%, 6/153).
- Significant decline in oral HPV detection with years since first sexual activity (>4 vs 1 year, OR 0.45 [P=.03 for trend]).
- HPV prevalence (all types) was 83% lower in vaccinated vs unvaccinated (OR 0.17; 95% CI, 0.04-0.68), remaining protective after adjusting for concurrent detection of 4vHPV cervical HPV types (OR 0.20; 95% CI, 0.04-1.00).
- 88% of detected oral HPV cleared
- Longitudinal cohort study evaluating oral HPV prevalence in sexually active urban female adolescents, association with HPV vaccine receipt, October 2007-March 2017.
- Funding: NIH, NCI.
- Single site.
- Insufficiently powered to assess HPV acquisition risk, vaccine benefit/HPV type.